Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692712 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
A Phase 3 study of Hereditary Spastic Paraplegia Type 50, sponsored by Elpida Therapeutics SPC.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06692712 is a Phase 3 study of Hereditary Spastic Paraplegia Type 50 that is actively recruiting participants, run by Elpida Therapeutics SPC. The registered enrollment target is 24 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06692712, a Phase 3 study of Hereditary Spastic Paraplegia Type 50, is actively recruiting participants, sponsored by Elpida Therapeutics SPC.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Conditions Studied
Interventions
- GENETIC MELPIDA
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
Other
- Sant Joan de Deu - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06692712
The ClinicalTrials.gov registry entry for NCT06692712 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elpida Therapeutics SPC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Spastic Paraplegia Type 50 appearing as the primary indexed condition, and to 1 intervention - of which MELPIDA is the first listed.
NCT06692712 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06692712 about?
NCT06692712 is a clinical study titled "Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.". Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
What is the current status of trial NCT06692712?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-02-01. Estimated completion is 2032-06-01.
What conditions does trial NCT06692712 study?
This clinical trial studies the following conditions: Hereditary Spastic Paraplegia Type 50.
What interventions are being tested in trial NCT06692712?
The interventions under investigation include: MELPIDA (GENETIC).
Who is sponsoring clinical trial NCT06692712?
This trial is sponsored by Elpida Therapeutics SPC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692712 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.